Inhaled corticosteroids for stable chronic obstructive pulmonary disease

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Clinical Trials

Background:

• The use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) remains controversial, with conflicting findings from meta-analyses.
• International guidelines suggest selective ICS use in COPD management.

Purpose of the Study:

• To evaluate the efficacy and safety of inhaled corticosteroids (ICS) in stable COPD patients.
• To assess objective and subjective outcomes related to ICS therapy in COPD.

Main Methods:

• Systematic review of randomized controlled trials comparing ICS with placebo in COPD patients.
• Searches conducted on the Cochrane Airways Group Specialised Register up to July 2011.
• Primary outcome: change in lung function (FEV1); secondary outcomes included mortality, exacerbations, quality of life, and safety.

Main Results:

• Long-term ICS use did not consistently reduce the rate of FEV1 decline in COPD patients.
• ICS significantly reduced the rate of exacerbations and slowed the decline in quality of life.
• Increased risks of oropharyngeal candidiasis, hoarseness, and pneumonia were observed with ICS use.

Conclusions:

• Clinicians and patients must balance the benefits of ICS (reduced exacerbations, improved quality of life) against risks (pneumonia, candidiasis).
• The potential benefit of ICS on FEV1 decline requires careful consideration.